Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations

Opinion
Video

Panelists discuss how the decision between quadruplet versus triplet therapy depends on multiple factors, including cytogenetic risk status, insurance coverage/drug access, patient fitness to tolerate additional toxicity, and the strength of evidence supporting improved outcomes with 4-drug combinations.

Recent Videos
4 experts in this video
4 experts in this video
7 experts are featured in this series.
7 experts are featured in this series.
7 experts are featured in this series.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Related Content